
Regentis Biomaterials Ltd.
RGNTAMEXHealthcareMedical - Instruments & Supplies
Previous close
$2.10
+$0.04 · +1.94%
RGNT company overview
Regular session · ET · Market data may be delayed.
Company profile
Company websiteRegentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- Headquarters
- IL
- CEO
- Ehud Geller
- Listed since
- Dec 4, 2025
- Employees
- 10
Market position
Day range
Current $2.10
52-week range
Current $2.10
- Open
- $2.05
- Previous close
- $2.06
- Volume
- 37.13K
- 0.01× average
- Average volume
- 5.4M
- Average daily volume
- Market cap
- 14.75M USD
- Beta
- -0.69
- Market reference 1
- 50-day average
- $2.8998
- -27.58% below average
- 200-day average
- $3.8404
- -45.32% below average
RGNT peers
Continue in GoAI
Research RGNTresearch.disclaimer





